JPMorgan Chase & Co. Purchases Shares of 6,682 AlloVir, Inc. (NASDAQ:ALVR)

JPMorgan Chase & Co. purchased a new stake in shares of AlloVir, Inc. (NASDAQ:ALVR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 6,682 shares of the company’s stock, valued at approximately $180,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of AlloVir during the 3rd quarter valued at about $32,219,000. Massachusetts Financial Services Co. MA bought a new stake in shares of AlloVir during the 3rd quarter valued at about $16,942,000. State Street Corp bought a new stake in shares of AlloVir during the 3rd quarter valued at about $6,876,000. CWM LLC bought a new stake in shares of AlloVir during the 3rd quarter valued at about $2,736,000. Finally, California Public Employees Retirement System purchased a new position in shares of AlloVir during the 3rd quarter valued at about $1,061,000. Institutional investors and hedge funds own 2.50% of the company’s stock.

NASDAQ ALVR opened at $38.44 on Friday. The business has a 50 day simple moving average of $37.96. AlloVir, Inc. has a 12 month low of $18.15 and a 12 month high of $48.96.

AlloVir (NASDAQ:ALVR) last posted its quarterly earnings results on Sunday, November 15th. The company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.28). As a group, analysts anticipate that AlloVir, Inc. will post -1.96 earnings per share for the current year.

A number of research analysts have recently weighed in on ALVR shares. Zacks Investment Research cut AlloVir from a “hold” rating to a “sell” rating in a research report on Thursday, November 12th. ValuEngine raised AlloVir from a “hold” rating to a “buy” rating in a research report on Thursday, October 1st. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $46.67.

AlloVir Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

See Also: The role of implied volatility with call option volume

Institutional Ownership by Quarter for AlloVir (NASDAQ:ALVR)

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.